Dianthus Therapeutics, Inc. /DE/ Lease, Cost
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Lease, Cost of $109.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ lease, cost for the quarter ending 2026-06-30 was $109.00K, a 0.93% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ lease, cost for the quarter ending 2026-03-31 was $108.00K, a 20.00% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ lease, cost for the quarter ending 2025-12-31 was $109.00K, a 10.66% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ lease, cost for the quarter ending 2025-09-30 was $88.00K, a 20.72% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ lease, cost for fiscal 2025 was $440.00K, a 3.08% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ lease, cost for fiscal 2024 was $454.00K, a 15.23% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ lease, cost for fiscal 2023 was $394.00K, a 66.95% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ lease, cost for fiscal 2022 was $236.00K.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $109.00K 10-Q · filed 2026-08-04 | $217.00K 10-Q · filed 2026-08-04 | $326.00K derived: sum of 3 quarters · filed 2026-08-04 | $414.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $108.00K 10-Q · filed 2026-05-05 | $217.00K derived: sum of 2 quarters · filed 2026-05-05 | $305.00K derived: sum of 3 quarters · filed 2026-05-05 | $413.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $197.00K derived: sum of 2 quarters · filed 2026-03-09 | $305.00K derived: sum of 3 quarters · filed 2026-08-04 | $440.00K 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $88.00K 10-Q · filed 2025-11-05 | $196.00K derived: sum of 2 quarters · filed 2026-08-04 | $331.00K 10-Q · filed 2025-11-05 | $453.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $108.00K 10-Q · filed 2026-08-04 | $243.00K 10-Q · filed 2026-08-04 | $365.00K derived: sum of 3 quarters · filed 2026-08-04 | $476.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $135.00K 10-Q · filed 2026-05-05 | $257.00K derived: sum of 2 quarters · filed 2026-05-05 | $368.00K derived: sum of 3 quarters · filed 2026-05-05 | $478.00K derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $233.00K derived: sum of 2 quarters · filed 2026-03-09 | $343.00K derived: sum of 3 quarters · filed 2026-03-09 | $454.00K 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $111.00K 10-Q · filed 2025-11-05 | $221.00K derived: sum of 2 quarters · filed 2025-11-05 | $332.00K 10-Q · filed 2025-11-05 | $443.00K derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $110.00K 10-Q · filed 2025-08-07 | $221.00K 10-Q · filed 2025-08-07 | $332.00K derived: sum of 3 quarters · filed 2025-08-07 | $427.00K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $111.00K 10-Q · filed 2025-05-12 | $222.00K derived: sum of 2 quarters · filed 2025-05-12 | $317.00K derived: sum of 3 quarters · filed 2025-05-12 | $411.00K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $206.00K derived: sum of 2 quarters · filed 2025-03-11 | $300.00K derived: sum of 3 quarters · filed 2025-03-11 | $394.00K 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $95.00K 10-Q · filed 2024-11-07 | $189.00K derived: sum of 2 quarters · filed 2024-11-07 | $283.00K 10-Q · filed 2024-11-07 | $371.00K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $94.00K 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2023-08-03 | $188.00K 10-Q · filed 2024-08-08 | $2.09M 10-Q · filed 2023-08-03 | $276.00K derived: sum of 3 quarters · filed 2024-08-08 | $349.00K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $94.00K 10-Q · filed 2024-05-09 | $2.09M 10-Q · filed 2023-05-15 | $182.00K derived: sum of 2 quarters · filed 2024-05-09 | $255.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.86M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $161.00K derived: sum of 2 quarters · filed 2024-03-21 | $1.77M derived: sum of 3 quarters · filed 2024-03-21 | $236.00K 10-K · filed 2024-03-21 | $7.81M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $73.00K 10-Q · filed 2023-11-09 | $2.04M 10-Q · filed 2022-11-03 | $1.68M derived: sum of 2 quarters · filed 2023-11-09 | $148.00K 10-Q · filed 2023-11-09 | $5.76M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $1.60M 10-Q · filed 2023-08-03 | $3.71M 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | $2.11M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $17.00K 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |